Novartis Renin Inhibitor Rasilez Approved In China For Hypertension
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Novartis has received regulatory approval in China for Rasilez (aliskiren) for treatment of high blood pressure alone or as a combination therapy with other anti-hypertension drugs, the Swiss company announced July 20. Aliskiren is marketed as Tekturna in the U.S
You may also be interested in...
Jiangbo Launches Generic Of Astrazeneca's Plendil, Targeting 153 Million Hypertension Patients In China
SHANGHAI - Nasdaq-listed Chinese pharma Jiangbo received approval from China's State FDA to manufacture Felodipine Sustained Release Tablets, a generic version of Plendil (felodipine)
Astellas Obtains Additional Indication For Prograf in Japan; Pfizer, GSK, Novartis Also Gain
Astellas Pharma received July 7 additional indication approval for its best-selling immunosuppressant Prograf (tacrolimus) for moderate to severe refractory ulcerative colitis in Japan
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).